The elevated P/S ratio reflects the market's willingness to assign value to the underlying intellectual property and vaccine platform despite the absence of recurring revenue. This valuation implies that the market anticipates a significant, non-linear value inflection point, likely tied to upcoming clinical readouts, which may render traditional valuation metrics largely irrelevant in the near term.

The negative ROIC trend highlights the inherent difficulty of compounding capital in a pre-revenue biotech model where R&D expenditures are mandatory and success is binary. Investors should monitor whether future milestone payments can offset this structural decay, though current figures suggest that the company is currently consuming rather than creating shareholder value.

This compression suggests that the company's ability to withstand operational stress without external financing is severely limited. The rapid shift in liquidity ratios warrants close investigation, as it may indicate an impending need for capital markets access to sustain the current research pipeline.